NOXXON Pharma
  • About
    • Management
    • Supervisory Board
    • Careers
    • Collaborations
  • Pipeline
    • Pipeline
    • NOX-A12
    • NOX-E36
  • Scientific Approach
    • Tumor Microenvironment
    • Technology
    • Scientific Publications
  • Investors
    • NOXXON in brief
    • Press Releases
    • Documentation
    • Corporate Governance
    • NOXXON and the Market
  • Contact
  • french
  • linkedin
  • twitter

About NOXXON

NOXXON’s oncology-focused pipeline acts by breaking the tumor protection barrier and blocking tumor repair. By neutralizing chemokines in the tumor micro-environment (TME), NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact. Building on extensive clinical experience and safety data, lead program NOX-A12 has delivered top-line data from a combination trial with the immuno-oncology checkpoint inhibitor, Keytruda®, in metastatic colorectal and pancreatic cancer patients with the latest update published in April 2020; further studies are being planned in these indications. In September 2019 NOXXON initiated an additional trial of NOX-A12 in brain cancer in combination with radiotherapy. The combination of NOX-A12 and radiotherapy has been granted orphan drug status in the US and EU for the treatment of certain brain cancers. The company’s second clinical-stage asset, NOX-E36 is a Phase 2 ready TME asset targeting the innate immune system. NOXXON plans to test NOX-E36 in patients with solid tumors both as a monotherapy and in combination.

 

• Download the latest update report on NOXXON by Aurgalys
➥ See all reports on NOXXON here

 

Press Release

Berlin, Germany

2021, January 19
08:00 a.m.

Half-yearly report on the liquidity contract with Invest Securities

2020, December 29
08:00 p.m.

NOXXON announces initiation of NOX-A12 manufacturing for future clinical studies

2020, November 09
08:00 a.m.

NOXXON announces that Data Safety Monitoring Board validates further NOX-A12 dose escalation in Phase 1/2 brain cancer study


Events

ESMO Immuno-Oncology

Aram Mangasarian, Jarl Ulf Jungnelius
December 9-12, Virtual Congress


* Spiegelmer® is a registered trademark of NOXXON Pharma

Imprint | Disclaimer | Privacy Policy |


© NOXXON Pharma 2021

Usage of Cookies

We use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about our use of cookies can be found in our privacy policy. If you continue to use this website we will assume that you agree with the usage of cookies. You can prevent cookies from being installed or delete them from your computer. How this works, is explained in our privacy policy.

You have declined cookies. This decision can be reversed.

You have allowed cookies to be placed on your computer.

Usage of Cookies

We use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about our use of cookies can be found in our privacy policy. If you continue to use this website we will assume that you agree with the usage of cookies. You can prevent cookies from being installed or delete them from your computer. How this works, is explained in our privacy policy.